Akouos Inc. (AKUS)

https://www.akouos.com

Akouos is a precision genetic medicine company developing gene therapies that restore and preserve hearing. Leveraging its adeno-associated viral vectors (AAV)-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear Infirmary and Lonza, Inc. *

	Start	2017-01-01 splitoff
	Industry	gene therapy
	Industry 2	adeno-associated viral vector (AAV vector)

	Region	Boston, MA
	Country	United States (USA)
	City	n. a. Boston, MA
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: BioArctic AB. (8/7/18). "Press Release: BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer’s Disease from a Research Project Jointly Owned with Eisai". Stockholm.

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Akouos Inc. (AKUS)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)